Online citations, reference lists, and bibliographies.
← Back to Search

Interleukin 10 Reduces The Incidence Of Pancreatitis After Therapeutic Endoscopic Retrograde Cholangiopancreatography.

J. Deviére, O. le Moine, J. van Laethem, P. Eisendrath, A. Ghilain, N. Severs, M. Cohard
Published 2001 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND & AIMS Prophylactic administration of interleukin (IL)-10 decreases the severity of experimental pancreatitis. Prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in humans is a unique model to study the potential role of IL-10 in this setting. METHODS In a single-center, double-blind, randomized, placebo-controlled study, the effect of a single injection of 4 microg/kg (group 1) or 20 microg/kg (group 2) IL-10 was compared with that of placebo (group 0), all administered 30 minutes before therapeutic ERCP. The primary endpoint was the effect of IL-10 on serum levels of amylases and lipases measured 4, 24, and 48 hours after ERCP. The secondary objective was to evaluate changes in plasma cytokines (IL-6, IL-8, tumor necrosis factor) at the same time points and the incidence of acute pancreatitis in the 3 groups. Subjects undergoing a first therapeutic ERCP were eligible for inclusion. RESULTS A total of 144 patients were included. Seven were excluded based on intention to treat (n = 1) or per protocol (n = 6). Forty-five, 48, and 44 patients remained in groups 0, 1, and 2, respectively. The 3 groups were comparable for age, sex, underlying disease, indication for treatment, type of treatment, and plasma levels of C-reactive protein (CRP), cytokines, and hydrolases at baseline. No significant difference was observed in CRP, cytokine, and hydrolase plasma levels after ERCP. Forty-three patients developed hyperhydrolasemia (18 in group 0, 14 in group 1, and 11 in group 2; P = 0.297), and 19 patients developed acute clinical pancreatitis (11 in group 0, 5 in group 1, 3 in group 2; P = 0.038). Two severe cases were observed in the placebo group. No mortality related to ERCP was observed. Logistic regression identified 3 independent risk factors for post-therapeutic ERCP pancreatitis: IL-10 administration (odds ratio [OR], 0.46; 95% confidence interval [95% CI], 0.22-0.96; P = 0.039), pancreatic sphincterotomy (OR, 5.04; 95% CI, 1.53-16.61; P = 0.008), and acinarization (OR, 8.19; 95% CI, 1.83-36.57; P = 0.006). CONCLUSIONS A single intravenous dose of IL-10, given 30 minutes before the start of the procedure, independently reduces the incidence of post-therapeutic ERCP pancreatitis.
This paper references
10.1136/gut.40.1.80
Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis.
H. Messmann (1997)
10.1016/S0039-6060(96)80299-6
Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice.
A. M. Kusske (1996)
10.1136/gut.43.3.408
Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice
J. van Laethem (1998)
10.1016/S0016-5107(00)70402-0
Prevention of post-ERCP pancreatitis.
G. Haber (2000)
10.1136/BMJ.310.6973.170
Multiple significance tests: the Bonferroni method.
J. Bland (1995)
10.1159/000051450
Pathophysiology of Pancreatitis
A. Saluja (1999)
10.1016/S0895-4356(96)00236-3
A simulation study of the number of events per variable in logistic regression analysis.
P. Peduzzi (1996)
10.1148/RADIOLOGY.156.3.4023241
Acute pancreatitis: prognostic value of CT.
E. Balthazar (1985)
10.1093/CLINIDS/20.5.1236
Antibiotic prophylaxis for infectious complications after therapeutic endoscopic retrograde cholangiopancreatography: a randomized, double-blind, placebo-controlled study.
B. Byl (1995)
10.1159/000051455
New Approaches to Acute Pancreatitis: Role of Inflammatory Mediators
J. Norman (1999)
10.1016/S0016-5107(99)70387-1
Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial.
R. Poon (1999)
10.1016/S0016-5085(97)70017-9
Chemokine gene expression in rat pancreatic acinar cells is an early event associated with acute pancreatitis.
T. Grady (1997)
10.1053/GAST.1997.V113.PM9247454
Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group.
S. V. van Deventer (1997)
10.1056/NEJM199609263351309
Complications of endoscopic sphincterotomy and their prevention.
K. Huibregtse (1996)
10.1136/gut.25.10.1107
Pancreatography in chronic pancreatitis: international definitions.
A. Axon (1984)
10.1016/S0016-5085(98)70031-9
Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction.
P. Tarnasky (1998)
10.1016/S0016-5107(90)71115-7
Sphincter of Oddi manometry: decreased risk of clinical pancreatitis with use of a modified aspirating catheter.
S. Sherman (1990)
10.1056/NEJM197812142992410
A show of confidence.
K. Rothman (1978)
10.1056/NEJM199609263351301
Complications of endoscopic biliary sphincterotomy.
M. Freeman (1996)
10.1002/BJS.1800821039
Randomized, double‐blind phase II trial of Lexipafant, a platelet‐activating factor antagonist, in human acute pancreatitis
A. Kingsnorth (1995)
10.1016/S0016-5107(99)70385-8
Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group.
M. Freeman (1999)
10.1016/S0016-5107(98)70121-X
Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study.
S. Loperfido (1998)
10.1006/JSRE.1997.5289
Mechanism of increased lung injury after acute pancreatitis in IL-10 knockout mice.
B. Gloor (1998)
10.1016/S0016-5107(99)70386-X
Features that may predict hospital admission following outpatient therapeutic ERCP.
K. Ho (1999)
10.1016/0016-5085(95)90158-2
Interleukin 10 prevents necrosis in murine experimental acute pancreatitis.
J. van Laethem (1995)
10.1016/0016-5085(91)90735-4
Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts.
S. Sherman (1991)
10.1056/NEJM199609263351302
Gabexate mesilate for the prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography.
G. Cavallini (1996)
10.2307/2532320
Practical statistics for medical research
D. Altman (1990)
10.1016/S1091-255X(98)80033-4
Hepatic Kupffer cell blockade reduces mortality of acute hemorrhagic pancreatitis in mice
B. Gloor (2007)
10.1148/RADIOLOGY.203.2.9114101
Pancreatic duct: morphologic and functional evaluation with dynamic MR pancreatography after secretin stimulation.
C. Matos (1997)
10.1136/bmj.316.7139.1236
What's wrong with Bonferroni adjustments
T. Perneger (1998)
10.1016/S0016-5107(00)70377-4
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
A. Andriulli (2000)
10.1046/J.1365-2168.1997.00512.X
Prospective placebo‐controlled randomized trial of lexipafant in predicted severe acute pancreatitis
C. Mckay (1997)
10.1016/S0016-5107(05)80542-5
Complications of major papilla endoscopic pancreatic sphincterotomy: A review of 106 patients
E. Esber (1995)
10.1056/NEJM199609263351302
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
G. Cavallini (1996)
10.1053/GAST.1997.V112.PM9041259
Interleukin 10 reduces the severity of acute pancreatitis in rats.
A. Rongione (1997)
10.1016/S0016-5107(91)70740-2
Endoscopic sphincterotomy complications and their management: an attempt at consensus.
P. Cotton (1991)



This paper is referenced by
Preventing post-ERCP pancreatitis: where are we?
P. Testoni (2003)
10.1053/j.gastro.2012.12.042
Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.
L. Zheng (2013)
10.1053/GE.2003.V57.AMGE030576633
Complications of ERCP.
J. Mallery (2003)
10.2165/00003495-200363170-00003
Pharmacological Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
H. Pande (2012)
stoneson the management of common bile duct
M. Lombard (2008)
The Prevention, recognition and treatment of post-ERCP pancreatitis.
Nison Badalov (2009)
Association between serum interleukin-35 levels and severity of acute pancreatitis.
Yili Zhang (2015)
10.1136/gut.2008.153098
Role of hedgehog signalling in bile ductular cells
I. Hines (2008)
10.1038/s41575-019-0158-2
New insights into acute pancreatitis
P. J. Lee (2019)
10.1016/J.DLD.2006.04.001
Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis.
P. Testoni (2006)
10.1016/J.GIEC.2006.11.002
Minimizing complications in endoscopic retrograde cholangiopancreatography and sphincterotomy.
Jeremy S Rochester (2007)
10.4021/gr2008.11.1238
Dynamic Changes of Soluble Fas and IL-2/IL-10 in serum and Fas Expression in Lung in the Rats of Acute Necrotizing Pancreatitis
J. Zhang (2008)
10.1007/S005340200049
Cytokine storm in acute pancreatitis.
R. Makhija (2002)
10.1111/j.1572-0241.2006.00950.x
Pharmacotherapy for the Prevention of Post-ERCP Pancreatitis
Erina N. Foster (2007)
10.1016/S1542-3565(04)00295-2
Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
A. Andriulli (2004)
10.1016/S0016-5107(04)00353-0
Prevention of post-ERCP pancreatitis: a comprehensive review.
M. Freeman (2004)
Anti-cytokine strategies in acute pancreatitis: pathophysiological insights and clinical implications.
B. Rau (2005)
10.1385/1592598153
Pancreatitis and Its Complications
C. Forsmark (2005)
10.1007/BF03020309
Pancréatite aiguë compliquant la cholanglo-pancréatographie rétrograde endoscopique (CPRE) et la ponction dirigée sous échoendoscopie
M. Barthet (2008)
10.4318/TJG.2011.0302
Prevention of post-ERCP pancreatitis.
Ü. Sarıtaş (2011)
10.5772/26194
Endoscopic Retrograde Cholangiopancreatography-Related Acute Pancreatitis – Identification, Prophylaxis and Treatment
A. González-Ojeda (2012)
Complications à court terme de la cholangio-pancréatographie rétrograde endoscopique (CPRE) diagnostique et thérapeutique
M. Barthet (2002)
10.1111/j.1572-0241.2006.00495.x
A Strong Association Between Down-Regulation of HLA-DR Expression and the Late Mortality in Patients with Severe Acute Pancreatitis
Yu-Pin Ho (2006)
TRYPSIN-RELATED MARKERS IN THE SEVERITY ASSESSMENT OF ACUTE PANCREATITIS A CLINICAL STUDY
Helsinki Finland (2004)
10.1111/j.1440-1746.2011.07011.x
Differential roles of inflammatory cells in pancreatitis
J. Mayerle (2012)
10.1016/J.TGIE.2014.09.004
Post–endoscopic retrograde cholangiopancreatography pancreatitis: Overview and pathophysiology
Efstratios Koutroumpakis (2014)
10.1016/J.EMCHG.2005.01.009
Traitement endoscopique de la pancréatite chronique
L. Heyries (2004)
10.1016/j.gie.2008.11.042
Does glyceryl nitrate prevent post-ERCP pancreatitis? A prospective, randomized, double-blind, placebo-controlled multicenter trial.
C. Nøjgaard (2009)
10.1097/MPA.0b013e31819777d5
Efficacy of Recombinant Human Interleukin-10 in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in Subjects With Increased Risk
S. Sherman (2009)
10.1159/000492313
Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in the Indomethacin Era – A Prospective Study
David Noiva Perdigoto (2018)
10.1111/apt.12534
Systematic review with network meta‐analysis: pharmacological prophylaxis against post‐ERCP pancreatitis
V. Akshintala (2013)
10.1016/S0016-5107(02)70178-8
Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study.
F. Prat (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar